Literature DB >> 18652097

Fasting glycemia in sleep disordered breathing: lowering the threshold on oxyhemoglobin desaturation.

Katherine Stamatakis1, Mark H Sanders, Brian Caffo, Helaine E Resnick, Dan J Gottlieb, Reena Mehra, Naresh M Punjabi.   

Abstract

STUDY
OBJECTIVES: Commonly used definitions of sleep-disordered breathing (SDB) are based on identifying discrete events of breathing abnormalities during sleep that are accompanied by an oxyhemoglobin desaturation (delta SaO2) of at least 4%. However, it is not known whether disordered breathing events with oxyhemoglobin desaturation less than 4% are associated with clinical sequelae such as abnormalities in fasting glycemia.
DESIGN: Cross-sectional study. SUBJECTS AND
SETTING: Participants from the Sleep Heart Health Study (SHHS) with a fasting glucose measurement made within a year of the baseline polysomnogram. MEASUREMENTS AND
RESULTS: SDB severity was defined using the apnea-hypopnea index (AHI) and the hypopnea index (HI) by counting events with different levels of oxyhemoglobin desaturation (0.0%-1.9%, 2.0%-2.9%, 3.0%-3.9%, > or = 4.0%). Fasting glucose levels were used to classify individuals into normal (<100 mg/dL), impaired (100-125 mg/dL), and diabetic (> or = 126 mg/dL) groups. Ordinal logistic regression was used to determine the adjusted relative odds of an abnormal glucose value across quartiles of the hypopnea index, independent of factors such as age, body mass index, waist circumference, and usual sleep duration. The prevalence of impaired and diabetic fasting glucose in the analytical sample was 32.9% and 5.8%, respectively. The covariate-adjusted relative odds of impaired or diabetic fasting glucose in the highest versus the lowest AHI quartile was 1.35 (95% CI: 1.04-1.76) for events with a delta SaO2 > or = 4.0%, 1.72 (95% CI: 1.20-2.48) for events with a delta SaO2 between 3.0%-3.9%, 1.41 (95% CI: 1.07-1.86) for events with a delta SaO2 between 2.0%-2.9%, and 1.07 (95% CI: 0.84-1.37) for events with a delta SaO2 between 0.0%-1.9%. The corresponding odds ratios for the HI were 1.47 (95% CI: 1.13-1.92), 2.25 (95% CI: 1.59-3.19), 1.44 (95% CI: 1.09-1.90), and 1.15 (95% CI: 0.90-1.47), respectively.
CONCLUSIONS: The results of this study indicate that SDB events accompanied by oxyhemoglobin desaturation of between 2% to 4% are associated with fasting hyperglycemia. These findings suggest that milder degrees of SDB may predispose to adverse metabolic outcomes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18652097      PMCID: PMC2491502     

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  55 in total

1.  EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association.

Authors: 
Journal:  Sleep       Date:  1992-04       Impact factor: 5.849

2.  Associations between alcohol consumption and insulin sensitivity and cardiovascular disease risk factors: the Insulin Resistance and Atherosclerosis Study.

Authors:  R A Bell; E J Mayer-Davis; M A Martin; R B D'Agostino; S M Haffner
Journal:  Diabetes Care       Date:  2000-11       Impact factor: 19.112

3.  Impact of sleep debt on metabolic and endocrine function.

Authors:  K Spiegel; R Leproult; E Van Cauter
Journal:  Lancet       Date:  1999-10-23       Impact factor: 79.321

4.  Alcohol consumption, Type 2 diabetes mellitus and impaired glucose tolerance in middle-aged Swedish men.

Authors:  S Carlsson; N Hammar; S Efendic; P G Persson; C G Ostenson; V Grill
Journal:  Diabet Med       Date:  2000-11       Impact factor: 4.359

5.  The Sleep Heart Health Study: design, rationale, and methods.

Authors:  S F Quan; B V Howard; C Iber; J P Kiley; F J Nieto; G T O'Connor; D M Rapoport; S Redline; J Robbins; J M Samet; P W Wahl
Journal:  Sleep       Date:  1997-12       Impact factor: 5.849

6.  The change of interleukin-6 and tumor necrosis factor in patients with obstructive sleep apnea syndrome.

Authors:  H Liu; J Liu; S Xiong; G Shen; Z Zhang; Y Xu
Journal:  J Tongji Med Univ       Date:  2000

7.  Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia.

Authors:  A N Vgontzas; D A Papanicolaou; E O Bixler; K Hopper; A Lotsikas; H M Lin; A Kales; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

8.  Neurocirculatory consequences of intermittent asphyxia in humans.

Authors:  A Xie; J B Skatrud; D C Crabtree; D S Puleo; B M Goodman; B J Morgan
Journal:  J Appl Physiol (1985)       Date:  2000-10

9.  The role of habitual snoring and obesity in the development of diabetes: a 10-year follow-up study in a male population.

Authors:  A Elmasry; C Janson; E Lindberg; T Gislason; M A Tageldin; G Boman
Journal:  J Intern Med       Date:  2000-07       Impact factor: 8.989

Review 10.  The perils of portliness: causes and consequences of visceral adiposity.

Authors:  C T Montague; S O'Rahilly
Journal:  Diabetes       Date:  2000-06       Impact factor: 9.461

View more
  32 in total

Review 1.  New developments in the use of positive airway pressure for obstructive sleep apnea.

Authors:  Lucas M Donovan; Schafer Boeder; Atul Malhotra; Sanjay R Patel
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

2.  Development of the National Healthy Sleep Awareness Project Sleep Health Surveillance Questions.

Authors:  Timothy I Morgenthaler; Janet B Croft; Leslie C Dort; Lauren D Loeding; Janet M Mullington; Sherene M Thomas
Journal:  J Clin Sleep Med       Date:  2015-09-15       Impact factor: 4.062

Review 3.  A review of signals used in sleep analysis.

Authors:  A Roebuck; V Monasterio; E Gederi; M Osipov; J Behar; A Malhotra; T Penzel; G D Clifford
Journal:  Physiol Meas       Date:  2013-12-17       Impact factor: 2.833

4.  Sleeping oxygen saturation, rapid eye movement sleep, and the adaptation of postprandial metabolic function in insulin sensitive and resistant individuals without diabetes.

Authors:  Karin A Garcia; William K Wohlgemuth; Ele Ferrannini; Andrea Mari; Alex Gonzalez; Armando J Mendez; Roberto Bizzotto; Jay S Skyler; Neil Schneiderman; Barry E Hurwitz
Journal:  Physiol Behav       Date:  2018-04-12

5.  Hypopnea Scoring Criteria: Time to Move Toward a Single Standardized Definition.

Authors:  Mukesh Kapoor
Journal:  J Clin Sleep Med       Date:  2018-11-15       Impact factor: 4.062

6.  Effects of different acute hypoxic regimens on tissue oxygen profiles and metabolic outcomes.

Authors:  Christian Reinke; Shannon Bevans-Fonti; Luciano F Drager; Mi-Kyung Shin; Vsevolod Y Polotsky
Journal:  J Appl Physiol (1985)       Date:  2011-07-07

7.  Intermittent hypoxia-induced glucose intolerance is abolished by α-adrenergic blockade or adrenal medullectomy.

Authors:  Jonathan C Jun; Mi-Kyung Shin; Ronald Devera; Qiaoling Yao; Omar Mesarwi; Shannon Bevans-Fonti; Vsevolod Y Polotsky
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-10-14       Impact factor: 4.310

8.  The new AASM criteria for scoring hypopneas: impact on the apnea hypopnea index.

Authors:  Warren R Ruehland; Peter D Rochford; Fergal J O'Donoghue; Robert J Pierce; Parmjit Singh; Andrew T Thornton
Journal:  Sleep       Date:  2009-02       Impact factor: 5.849

9.  Prevalence of type 2 diabetes in patients with obstructive sleep apnea in a multi-ethnic sample.

Authors:  Kamran Mahmood; Natasha Akhter; Kamal Eldeirawi; Ergün Onal; John W Christman; David W Carley; James J Herdegen
Journal:  J Clin Sleep Med       Date:  2009-06-15       Impact factor: 4.062

10.  Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine.

Authors:  Richard B Berry; Rohit Budhiraja; Daniel J Gottlieb; David Gozal; Conrad Iber; Vishesh K Kapur; Carole L Marcus; Reena Mehra; Sairam Parthasarathy; Stuart F Quan; Susan Redline; Kingman P Strohl; Sally L Davidson Ward; Michelle M Tangredi
Journal:  J Clin Sleep Med       Date:  2012-10-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.